The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The promise of combining venetoclax with gilteritinib for the treatment of FLT3-mutated AML
In this video, Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the promise of combining venetoclax with gilteritinib for the treatment of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), and highlights some recent data from a study evaluating this combination. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Clinical trial support – Abbvie, Servier, BMS
Consulting – Abbvie, Servier, BMS, Genentech, PureTech, Ipsen, Forma, Kite, Celgene, Amgen, Novartis, Takeda, Astellas, Immunogen, Mablytics, EnClear, Orum
